TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00647569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesh repair
Description: A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesh repair
Description: A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional facial closure
Description: The abdominal facia is closed with with continuous running suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional facial closure
Description: The abdominal facia is closed with with continuous running suture
Study: NCT01801371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BNOTA-PRGD2
Description: Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
Study: NCT04048733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patchy-type wireless 12-lead ECG
Description: Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
Study: NCT03834649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partially de-epithelized connective tissue graft
Description: graft procedures to obtain simultaneous tissue augmentation in the horizontal and vertical dimensions. The donor site was prepared with a full-thickness coronal dissection and a partial-thickness apical dissection.The objectives were to use a single procedure to achieve simultaneously apico-coronal and buccolingual augmentation,to have a smaller open wound in the donor site and less patient discomfort, and to guarantee better revascularization of the onlay section aided by the submerged connective tissue section of the graft.
Study: NCT00073840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levalbuterol
Description: * Levalbuterol 90 ųg QID (manufacturing sites A or B);~* Racemic Albuterol 180 ųg QID;~* Placebo QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levalbuterol
Description: * Levalbuterol 90 ųg QID (manufacturing sites A or B);~* Racemic Albuterol 180 ųg QID;~* Placebo QID
Study: NCT00125047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid Vi vaccine
Description: Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
Study: NCT00910975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon-alfa2a (Pegasys)
Description: Peg-interferon-alfa2a 180 µg per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (Copegus)
Description: Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
Study: NCT03834649

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucograft
Description: For preprosthetic defects, a standard mucosal augmentation procedure, which is well reported in the literature, was performed. The surgical site produced by the surgery leaves a denuded area supraperiosteally that is addressed by grafting with a xenogeneic collagen membrane (Mucograft).~purpose of the surgery is to improve the quantity of attached mucosa to facilitate the final dental reconstruction
Study: NCT00923949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 45 mg tablet daily by mouth for six weeks
Study: NCT04320641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACUPRESSURE
Description: Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACUPRESSURE
Description: Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.
Study: NCT03802214

Intervention type: DRUG
Intervention: Vedolizumab
Description: standard vedolizumab induction (300mg IV at week 0, 2, 6)

Intervention type: DRUG
Intervention: Vedolizumab
Description: standard vedolizumab induction (300mg IV at week 0, 2, 6)
Study: NCT01007630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: 0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
Study: NCT00970775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: oral solution, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution,single dose
Study: NCT02776748

Intervention type: DRUG
Group type: OTHER
Intervention: FTC/TDF PrEP
Description: Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
Study: NCT03861494

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Stroke Education
Description: In addition to the general stroke education materials and verbal education, the enhanced stroke education group will receive a personalized verbal and written information addressing the patient's specific risk factors including their current status and goals, laboratory values and goals, and current blood pressure and goal. Specific stroke type and etiology is discussed, medication including indication, dose, frequency, physical activity goals, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, and education over the importance of keeping follow up appointments including Stroke Clinic. Verbal feedback of key points is encouraged.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Stroke Education
Description: The usual stroke education group will receive general stroke education including written and verbal information about signs and symptoms of stroke, best practice to engage medical treatment if stroke occurs, general information about heart healthy diet and need for daily physical activity as well as need for compliance with medication recommendations. The education is incorporated with routine patient care and as allowed during quiet times. On the day of discharge, the patient will receive written materials reviewing stroke symptoms, risk factors, heart healthy diet and follow up appointments. The patient will receive written and verbal information about medications including indication, dose, frequency, physical activity goal, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, the importance of keeping follow up appointments including Stroke Clinic.
Study: NCT03970356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antibiotic stewardship intervention
Description: The intervention is multifaceted, consisting of the implementation of an algorithm for restrictive use of antibiotics as proposed in recent guidelines (Verenso, Dutch guideline), tailored in close collaboration with local stakeholders to the specific implementation setting, by means of a modified participatory-action research (PAR) approach. To support the process of intervention-tailoring and -implementation, a toolbox comprising of materials, aids and actions is developed to be used at the discretion of the local stakeholders to support implementation of the algorithm.The algorithm is congruent with the Swedish and Norwegian guidelines, which also promote more restrictive use of antibiotics in case of non-specific symptoms, even though the algorithm is more detailed.
Study: NCT00439049

Intervention type: DRUG
Intervention: modafinil
Description: 400 mg daily

Intervention type: DRUG
Intervention: d-amphetamine
Description: 60mg daily

Intervention type: DRUG
Intervention: L-Dopa
Description: 800/200mg daily

Intervention type: DRUG
Intervention: Naltrexone
Description: 50mg daily
Study: NCT00369629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.
Study: NCT00631631

Intervention type: DRUG
Intervention: Mifamurtide (L-MTP-PE)
Description: Solution for intravenous infusion
Study: NCT02536248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg/d for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg/d for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 6 weeks
Study: NCT00217633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Study: NCT01846780

Intervention type: PROCEDURE
Intervention: PTA & stenting
Description: PTA \& stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
Study: NCT03115190

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: General Practitioner diagnosis with Heart score
Description: All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
Study: NCT03064464

Intervention type: OTHER
Intervention: None Intervention
Description: It is observational study, no interventios to any of the three study arms

Intervention type: OTHER
Intervention: None Intervention
Description: It is observational study, no interventios to any of the three study arms

Intervention type: OTHER
Intervention: None Intervention
Description: It is observational study, no interventios to any of the three study arms
Study: NCT00931164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: dosage is by weight
Study: NCT03339895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pvı-guided
Description: pvı- guided total amount of crystalloid volume of fluid infused during colorectal surgery pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery If PVI value \<%13 and if MAP\>65mmHg continue with 2 ml/kg/h cristalloid infusion If PVI value \<%13 and if MAP\>65mmHg 5 mcg efedrin intravenous bolus till MAP\>65 mmHg If PVI value \>%13 and MAP\>65 mmHg infuse 250 ml Gelofusine bolus up to PVI value lowers to %13 every 5 minute If PVI value \>%13 and MAP \<65 mmHg infuse 250 ml Gelofusine bolus and 5 mcg efedrin intravenous up to PVI value lowers to %13

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional-guided
Description: traditional-guided total amount of crystalloid volume of fluid infused during colorectal surgery traditional-guided fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP \<65 mmHg or \<30%of basal value, infuse 250 ml Gelofusine bolus and 5 mcg efedrin If MAP\>65 mmHg no intervention
Study: NCT01992029

Intervention type: OTHER
Intervention: Clinical evaluation
Description: Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12

Intervention type: PROCEDURE
Intervention: Muscular biopsy
Description: Muscular biopsy at M0

Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Lumbar puncture at M0 and M12

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling at M0, M4, M4, M8 and M12

Intervention type: OTHER
Intervention: Neurological assessments
Description: Neurological assessments (MRC score and cognitive scales: MMS and BREF)

Intervention type: OTHER
Intervention: Neurological assessments
Description: Neurological assessments (MRC score and cognitive scales: MMS and BREF)

Intervention type: OTHER
Intervention: Neurological assessments
Description: Neurological assessments (MRC score and cognitive scales: MMS and BREF)

Intervention type: PROCEDURE
Intervention: Neuro-muscular biopsy and lumbar puncture
Description: Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy

Intervention type: PROCEDURE
Intervention: Muscular biopsy
Description: Muscular biopsy for patient explored for myopathy

Intervention type: PROCEDURE
Intervention: Muscular biopsy
Description: Muscular biopsy for patient explored for myopathy

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample for qRT PCR, detection and quantification for miRNA

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample for qRT PCR, detection and quantification for miRNA

Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample for qRT PCR, detection and quantification for miRNA

Intervention type: DEVICE
Intervention: Cervical spinal cord and brain MRI
Description: ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion

Intervention type: DEVICE
Intervention: Cervical spinal cord and brain MRI
Description: ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion

Intervention type: DEVICE
Intervention: Cervical spinal cord and brain MRI
Description: ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
Study: NCT00369629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.
Study: NCT01992029

Intervention type: DEVICE
Intervention: Cervical spinal cord and brain MRI
Description: ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
Study: NCT02825290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choriogonadotropin alfa
Study: NCT04658602

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preformed stainless steal crown cemented by glass ionomer lutting cement (Ketac cem,3M Espe)
Description: Covering the affected molar with preformed metal crown cemented by glass ionomer lutting cement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preformed stainless steal crown cemented by glass ionomer lutting cement (Ketac cem,3M Espe)
Description: Covering the affected molar with preformed metal crown cemented by glass ionomer lutting cement
Study: NCT01552499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applications of EpiFix
Study: NCT04203901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMN-001
Description: Autologous Dendritic Cell Therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab+Ipilimumab
Description: anti-PD-1 and anti-CTLA4 antibodies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab+Ipilimumab
Description: anti-PD-1 and anti-CTLA4 antibodies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib+Everolimus
Description: TKI+mTOR inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib+Everolimus
Description: TKI+mTOR inhibitors
Study: NCT02043886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose 50 mg by mouth given during Meal Test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
Study: NCT06028620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Focused-Cognitive Behavior Therapy
Description: TF-CBT consisted of 8 units in which different issues realted to trauma are reviewed. Units are: psychoeducation and parenting skills, relaxation techniques, affective expression and regulation, cognitive coping and processing, trauma narrative and processing, in vivo exposure, co-joint sessions and enhancing safety and future growth.
Study: NCT01869335

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI (magnetic resonance imaging)
Study: NCT02367950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 10 exercise sessions with a personal trainer
Study: NCT03512236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC Pram Ins
Description: Injection of BC Pram Ins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symlin® and Humulin®
Description: Injection of pramlintide and human insulin
Study: NCT00914420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrepide Trapidil eluting stent
Description: The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.~The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taxus drug eluting stent
Description: Paclitaxel Drug eluting stent manufactured by Boston Scientific
Study: NCT03512236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Injection of lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection of 0.9% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injection of 0.9% NaCl
Study: NCT00332202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, daily
Study: NCT03011645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Given by mouth, single dose of 60 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Given by mouth, single dose of 20 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Given by mouth, single dose.
Study: NCT02471690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oritavancin
Description: IV - Single dose 1200 mg Oritavancin
Study: NCT02129426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Sedation medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Sedation medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Sedation medication
Study: NCT02471690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose
Description: D5W 5% in Water